TABLE 3.
Asthma control outcomes in asthma patients aged ≥18 years in Sweden, Norway and Finland in 2018
| Sweden | Norway | Finland | ||||
| Mild-to-moderate | Severe | Mild-to-moderate | Severe | Mild-to-moderate | Severe | |
| Patients | 180 669 | 6477 | 122 144 | 6999 | 155 619 | 8476 |
| Recurrent exacerbations# (≥2 exacerbations) | 14 185 (8) | 4335 (67) | 6557 (5) | 4285 (61) | 8167 (5) | 5370 (63) |
| Asthma-related ED visit | 5616 (3) | 480 (7) | 3767 (2) | 825 (10) | ||
| Asthma-related hospital admission | 2404 (1) | 517 (8) | 2642 (2) | 925 (11) | ||
| High SABA use | 33 103 (18) | 2457 (38) | 24 877 (20) | 3292 (47) | 23 227 (15) | 3458 (41) |
| Uncontrolled asthma¶ | 43 985 (24) | 5167 (80) | 29 120 (24) | 5395 (77) | 30 070 (19) | 6587 (78) |
| Antibiotics | 28 029 (16) | 2220 (34) | 26 145 (21) | 3348 (48) | 57 642 (37) | 4882 (58) |
| Hospital attendance with pneumonia | 2197 (1) | 455 (7) | 3337 (2) | 1002 (12) | ||
Data are presented as n or n (%). ED: emergency department; SABA: short-acting β-agonist. #: defined as either a dispensation with burst oral corticosteroid (OCS) (Anatomical Therapeutic Chemical Classification code H02AB), or an asthma-related ED visit in 2018, or as an asthma-related hospital admission; ¶: defined as at least two OCS dispensations and/or asthma-related ED visits and/or at least one asthma-related admission and/or high SABA use (of ≥600 doses (puffs)).